Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Interferon beta-1a - Merck Serono

Next Previous
X
Search
Drug Profile

Interferon beta-1a - Merck Serono

Alternative Names: Interferon β-1a - Merck Serono; r-IFNβ-1a; Rebif; Rebif Rebidose; Rebif® modified formulation; Rebif® New Formulation; Rebif® reformulation; Rebif® Serum-free formulation; Recombinant human interferon beta-1a; RNF - Merck Serono; scIFNβ-1a

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Weizmann Institute of Science
  • Developer EMD Serono; Merck Serono
  • Class Antiasthmatics; Antineoplastics; Antivirals; Interferons; Vascular disorder therapies
  • Mechanism of Action Interferon beta-1a replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Multiple sclerosis
  • No development reported Hepatitis C; Human papillomavirus infections; Non-small cell lung cancer; Ulcerative colitis
  • Discontinued Crohn's disease; Rheumatoid arthritis

Most Recent Events

  • 13 Oct 2021 Efficacy data from the phase III REFLEXION trial in Multiple sclerosis presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-2021)
  • 13 Oct 2021 Additional efficacy data from the phase III REFLEX trial in Multiple sclerosis presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-2021)
  • 11 Sep 2019 Additional efficacy data from the phase III REFLEX trial in Multiple sclerosis presented at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-2019)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top